Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

Their objective was to evaluate the impact of angiotensin II receptor blockade with candesartan on the renal hemodynamic and urinary excretory responses to a progressive orthostatic stress in normal subjects.

Who Took Part

The age groups tagged for this paper are adults, men only.

Twenty healthy men were submitted to three levels of LBNP (0, -10, and -20 mbar or 0, -7.5, and -15 mm Hg) for 1 hour according to a crossover design with a minimum of 2 days between each level of LBNP.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

Systemic and renal hemodynamics, renal sodium excretions, and the hormonal response were measured hourly before, during, and for 2 hours after LBNP.

What Was Measured

PubMed files the paper under topics including Acute Disease, Angiotensin II, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Blood Pressure and Heart Rate.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Angiotensin II.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Kidney international), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.